{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:07:08Z","timestamp":1780463228954,"version":"3.54.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>We describe the clinical characteristics and the therapeutic effect of tocilizumab with Febrile Infection-Related Epilepsy Syndrome (FIRES). FIRES is characterized by super refractory status epilepticus (SRSE) in previously healthy children, following a febrile illness that manifests between 2 weeks and 24 hours prior to the onset of seizure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected and summarized the clinical data of two pediatric patients with FIRES and compare with those described previously in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elevated levels of IL-6 were observed in the two patient\u2019s blood samples. Patient 1 consented to receive tocilizumab on the 58th day of the disease progression, resulting in transient relief of seizures. Throughout the follow-up period, the patient remained unconscious and consistently experienced intermittent seizures. Patient 2 was administered tocilizumab on the 7th day of the disease course. During the six-month follow-up, no seizures were observed and no significant cognitive decline. Up to date, 7 patients of pediatric FIRES treated with tocilizumab have been reported. The clinical symptoms of the patients were relatively consistent, characterized by focal seizures and status epilepticus as the primary manifestations. Serum IL-6 may exhibit elevated or normal, whereas cerebrospinal fluid IL-6 demonstrated a significant elevation, indicating a lack of concordance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Now little has been known about the administration of tocilizumab in pediatric FIRES. We posit that early administration of tocilizumab (within 3 weeks from disease onset) positively impacts the treatment of FIRES.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1767388","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:55:33Z","timestamp":1780462533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Tocilizumab in pediatric febrile infection-related epilepsy syndrome"],"prefix":"10.3389","volume":"17","author":[{"given":"Lingyu","family":"Pang","sequence":"first","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Clinical Research Center for Child Health and Disease","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefang","family":"Liu","sequence":"additional","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Clinical Research Center for Child Health and Disease","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzhen","family":"Sun","sequence":"additional","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Clinical Research Center for Child Health and Disease","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Clinical Research Center for Child Health and Disease","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Lu","sequence":"additional","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Clinical Research Center for Child Health and Disease","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Du","sequence":"additional","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Clinical Research Center for Child Health and Disease","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Clinical Research Center for Child Health and Disease","place":["Shijiazhuang, China"]},{"name":"First Department of Neurology, Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.14553","article-title":"New-onset refractory status epilepticus and febrile infection-related epilepsy syndrome","volume":"62","author":"Specchio","year":"2020","journal-title":"Dev Med Child Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1150496","article-title":"A practical approach to in-hospital management of new-onset refractory status epilepticus\/febrile infection related epilepsy syndrome","volume":"14","author":"Sheikh","year":"2023","journal-title":"Front Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2023.09.008","article-title":"Febrile infection-related epilepsy syndrome in childhood: a clinical review and practical approach","volume":"111","author":"Van Baalen","year":"2023","journal-title":"Seizure"},{"key":"B4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13052-022-01389-1","article-title":"Febrile infection-related epilepsy syndrome (FIRES): a severe encephalopathy with status epilepticus. Literature review and presentation of two new cases","volume":"48","author":"Pavone","year":"2022","journal-title":"Ital J Pediatr"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000001940","article-title":"New-onset refractory status epilepticus: etiology, clinical features, and outcome","volume":"85","author":"Gaspard","year":"2015","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25374","article-title":"Tocilizumab treatment for new onset refractory status epilepticus","volume":"84","author":"Jun","year":"2018","journal-title":"Ann Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2329048X20979253","DOI":"10.1177\/2329048x20979253","article-title":"Interleukin-6 blockade with tocilizumab in anakinra-refractory febrile infection-related epilepsy syndrome (FIRES)","volume":"7","author":"Stredny","year":"2020","journal-title":"Child Neurol Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17591","article-title":"Treatment of new onset refractory status epilepticus\/febrile infection-related epilepsy syndrome with tocilizumab in a child and a young adult","volume":"64","author":"Girardin","year":"2023","journal-title":"Epilepsia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577142","article-title":"Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: experience in two patients","volume":"340","author":"Cantar\u00edn-Extremera","year":"2020","journal-title":"J Neuroimmunol"},{"key":"B10","article-title":"A case of febrile infection-related epilepsy syndrome in children successfully treated with tocilizumab and literature review","volume":"55","author":"Wang","year":"2022","journal-title":"Chin J Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113872","article-title":"Favorable outcomes and FDG-PET changes following tocilizumab treatment for febrile infection-related epilepsy syndrome in a child","volume":"146","author":"Wan","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14016","article-title":"Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions","volume":"59","author":"Hirsch","year":"2018","journal-title":"Epilepsia"},{"key":"B13","article-title":"International consensus recommendations for management of new onset refractory status epilepticus (NORSE) incl. febrile infection-related epilepsy syndrome (FIRES): statements and supporting evidence","volume":"63","author":"Wickstrom","year":"2022","journal-title":"Epilepsia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ana.26627","article-title":"Cytokines in newonset refractory status epilepticus predict outcomes","volume":"94","author":"Hanin","year":"2023","journal-title":"Ann Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03250.x","article-title":"Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children","volume":"52","author":"Kramer","year":"2011","journal-title":"Epilepsia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02535.x","article-title":"Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood","volume":"51","author":"Van Baalen","year":"2010","journal-title":"Epilepsia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309388","article-title":"Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus","volume":"86","author":"Sakuma","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16275","article-title":"Etiology is the key determinant of neuroinflammation in epilepsy: elevation of cerebrospinal fluid cytokines and chemokines in febrile infection-related epilepsy syndrome and febrile status epilepticus","volume":"60","author":"Kothur","year":"2019","journal-title":"Epilepsia"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.2147\/NDT.S177803","article-title":"Febrile infection-related epilepsy syndrome (FIRES): prevalence, impact and management strategies","volume":"15","author":"Serino","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrneurol.2010.178","article-title":"The role of inflammation in epilepsy","volume":"7","author":"Vezzani","year":"2011","journal-title":"Nat Rev Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1767388\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:55:57Z","timestamp":1780462557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1767388\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2026.1767388"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1767388","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1767388"}}